Phaseline

Targets › CDK7

CDK7 (Cyclin-dependent kinase 7): drug programs, companies and trials

2 programs from 2 companies in 2 trials: 2 Phase 1; Oncology; next expected readout Aug 2028.

Serine/threonine kinase involved in cell cycle control and in RNA polymerase II-mediated RNA transcription. As a cyclin-dependent kinase, CDK7 is activated by the binding to cyclin-H/CCNH and the CDK-activating kinase assembly factor MAT1. (UniProt, P50613)

Open in Phaseline: the race on CDK7, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
National Cancer Institute (NCI)Zotiraciclib
Cyclin-dependent kinase 1 inhibitor; Cyclin-dependent kinase 2 inhibitor; Cyclin-dependent kinase 7 inhibitor
CDK1, CDK2, CDK7, CDK9, FLT3Phase 1Brain TumorAug 2028
QurientQ901
Highly selective CDK7 inhibitor
CDK7Phase 1Advanced Cancer–

Conditions

Brain Tumor (1) Advanced Cancer (1)

Modalities

small molecule (1), mixed (1)

Companies

National Cancer Institute (NCI) (1) Qurient (1)

Related targets

CDK1 (1) CDK2 (1) CDK9 (1) FLT3 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.